A selective N-type Ca(2+)-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia.

Journal article

SNX-111 (NEUREX Corporation, Menlo Park, CA, U.S.A.) an omega-conopeptide, was tested for cytoprotection following normothermic ischemia using both a four-vessel occlusion model of severe forebrain ischemia and a model of transient middle cerebral artery occlusion focal ischemia. Adult male Wistar rats were subjected to 10 min of forebrain ischemia followed by 7 days of reperfusion. A single dose of SNX-111 (5 mg/kg) was injected intravenously following delays of either 6 or 24 h after reperf...

Expand abstract

Authors: Buchan, A; Gertler, S; Li, H; Xue, D; Huang, Z

• Publication status: Published
• Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
• Volume: 14
• Issue: 6
• Pages: 903-910
• Publication date: 1994-11-01
• DOI: 10.1038/jcbfm.1994.121
• EISSN: 1559-7016
• ISSN: 0271-678X
• Language: English
• Keywords: Peptides; Hippocampus; Rats, Inbred SHR; Calcium Channel Blockers; Male; Cerebral Infarction; Rats; omega-Conotoxins; Prosencephalon; Rats, Wistar; Survival Analysis; Animals; Cerebrovascular Circulation; Morbidity; Brain Ischemia